Taro Pharm Inds (TARO) 141.22 $TARO
Taro Announces Resignation of Chief Financial Officer
BusinessWire - Tue Jun 21, 4:20PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company"
announced today that it has accepted the resignation of its Chief Financial Officer, Michael Kalb, effective June 29, 2016. Mr. Kalb is leaving to accept the position of CFO at another public company.
TARO: 141.22 (-0.92)
Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2016
BusinessWire - Thu Jun 09, 4:16PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE: TARO, "Taro" announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2016, filed with the Securities and Exchange Commission (the "SEC", is available within the Investor Relations section of Taro's website at www.taro.com.
TARO: 141.22 (-0.92)
Taro Provides Results for Year Ended March 31, 2016
BusinessWire - Thu May 26, 5:33PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company" today provided unaudited financial results for the quarter and year ended March 31, 2016.
TARO: 141.22 (-0.92)
Taro to Announce Results for Year Ended March 31, 2016 on May 26, 2016
BusinessWire - Fri May 20, 3:14PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the year ended March 31, 2016, on Thursday, May 26, 2016.
TARO: 141.22 (-0.92)
Taro to Make Keveyis(TM) Available to Distributors Free of Cost
BusinessWire - Mon May 02, 7:59AM CDT
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company" today announced that its U.S. subsidiary, Taro Pharmaceuticals U.S.A., Inc., will now make Keveyis(TM) (dichlorphenamide) available to distributors at no cost for the treatment of primary periodic paralysis, an ultra-rare and debilitating disease. As a result, Taro will cease commercial sales and related promotional activities for Keveyis and bear all costs associated with its manufacture. In the near term, patients will continue to receive the medicine through Diplomat as the Company evaluates the best option for keeping pharmacy dispensing fees to patients as low as possible.
TARO: 141.22 (-0.92)
American CryoStem Corporation Retains Investor Relations Partners as Investor Relations Counsel
Marketwired - Fri Apr 01, 7:00AM CDT
American CryoStem Corporation (OTC PINK: CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced that it has retained Investor Relations Partners (IRP) to expand the Company's strategic investor relations program.
TARO: 141.22 (-0.92), HOT: 76.59 (-1.21)
Taro posts 3Q profit
Automated Insights - Wed Feb 10, 4:33PM CST
HAIFA BAY, Israel (AP) _ Taro Pharmaceutical Industries Ltd. (TARO) on Wednesday reported fiscal third-quarter profit of $189 million.
TARO: 141.22 (-0.92)
Taro Provides Results for December 31, 2015
BusinessWire - Wed Feb 10, 4:15PM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company" today provided unaudited financial results for the three and nine months ended December 31, 2015.
TARO: 141.22 (-0.92)
CORRECTING and REPLACING Taro to Announce Third Quarter Results on February 10, 2016
BusinessWire - Wed Feb 03, 1:57PM CST
The date at the end of the first paragraph of release dated February 2, 2016 should read: Wednesday, February 10, 2016 (instead of Tuesday, February 10, 2016).
TARO: 141.22 (-0.92)
Taro to Announce Third Quarter Results on February 10, 2016
BusinessWire - Tue Feb 02, 2:56PM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter and nine months ended December 31, 2015, after the close of market on Tuesday, February 10, 2016.
TARO: 141.22 (-0.92)
Taro Provides Results for September 30, 2015
BusinessWire - Tue Nov 03, 5:06PM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company" today provided unaudited financial results for the three and six months ended September 30, 2015.
TARO: 141.22 (-0.92)
Taro to Announce Second Quarter Results on November 3, 2015
BusinessWire - Tue Oct 27, 3:53PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the quarter and six months ended September 30, 2015, on Tuesday, November 3, 2015, after the close of the Market.
TARO: 141.22 (-0.92)
Taro Pharmaceutical Industries introduces Keveyis 50 mg tablets for treating primary hyperkalemic and hypokalemic periodic paralysis
M2 - Tue Sep 22, 3:16AM CDT
Pharmaceutical company Taro Pharmaceutical Industries (NYSE:TARO) disclosed on Monday the launch of Keveyis (dichlorphenamide) 50 mg Tablets for the treatment of primary hyperkalemic and hypokalemic periodic paralysis and related variants in the US market.
TARO: 141.22 (-0.92)
Taro's Keveyis(TM) (dichlorphenamide) 50 mg Tablets Now Available for the Treatment of Primary Hyperkalemic and Hypokalemic Periodic Paralysis
BusinessWire - Mon Sep 21, 12:28PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that Keveyis(TM) (dichlorphenamide) 50 mg Tablets, the first medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of primary hyperkalemic and hypokalemic periodic paralysis and related variants, is now available for appropriate patients through its specialty pharmacy partner, Diplomat. Periodic paralysis is a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis.[1] It is estimated to affect approximately 5,000 people in the United States, up to 70 percent of which are currently undiagnosed.[2]
TARO: 141.22 (-0.92)
Taro Pharmaceutical Industries wins US FDA approval for Keveyis 50 mg tablets for treating primary hyperkalemic and hypokalemic periodic paralysis
M2 - Tue Aug 11, 4:47AM CDT
Pharmaceutical company Taro Pharmaceutical Industries (NYSE:TARO) revealed on Monday the receipt of the US Food and Drug Administration's (FDA) approval for Keveyis (dichlorphenamide) 50 mg Tablets for the treatment of primary hyperkalemic and hypokalemic periodic paralysis.
TARO: 141.22 (-0.92)
FDA Approves Taro's Keveyis(TM) (dichlorphenamide) 50 mg Tablets for Primary Hyperkalemic and Hypokalemic Periodic Paralysis
BusinessWire - Mon Aug 10, 7:30AM CDT
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that the U.S. Food and Drug Administration (FDA) has approved Keveyis(TM) (dichlorphenamide) 50 mg Tablets for the treatment of primary hyperkalemic and hypokalemic periodic paralysis, a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis [1]. Keveyis is the first medicine approved by the FDA for the treatment of primary periodic paralysis, which is estimated to affect approximately 5,000 people in the United States [2].
TARO: 141.22 (-0.92)
Taro Provides Results for Quarter Ended June 2015
BusinessWire - Thu Aug 06, 4:19PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company" today provided unaudited financial results for the quarter ended June 30, 2015.
TARO: 141.22 (-0.92)
Taro to Announce First Quarter Results on August 6, 2015
BusinessWire - Thu Jul 30, 4:09PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter and three months ended June 30, 2015, after the close of market on Thursday, August 6, 2015.
TARO: 141.22 (-0.92)
Taro Announces Resignation of Chief Financial Officer
BusinessWire - Tue Jun 21, 4:20PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company"
announced today that it has accepted the resignation of its Chief Financial Officer, Michael Kalb, effective June 29, 2016. Mr. Kalb is leaving to accept the position of CFO at another public company. TARO: 141.22 (-0.92)
Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2016
BusinessWire - Thu Jun 09, 4:16PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE: TARO, "Taro"
announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2016, filed with the Securities and Exchange Commission (the "SEC", is available within the Investor Relations section of Taro's website at www.taro.com. TARO: 141.22 (-0.92)
Taro Provides Results for Year Ended March 31, 2016
BusinessWire - Thu May 26, 5:33PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company"
today provided unaudited financial results for the quarter and year ended March 31, 2016. TARO: 141.22 (-0.92)
Taro to Announce Results for Year Ended March 31, 2016 on May 26, 2016
BusinessWire - Fri May 20, 3:14PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the year ended March 31, 2016, on Thursday, May 26, 2016.
TARO: 141.22 (-0.92)
Taro to Make Keveyis(TM) Available to Distributors Free of Cost
BusinessWire - Mon May 02, 7:59AM CDT
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company"
today announced that its U.S. subsidiary, Taro Pharmaceuticals U.S.A., Inc., will now make Keveyis(TM) (dichlorphenamide) available to distributors at no cost for the treatment of primary periodic paralysis, an ultra-rare and debilitating disease. As a result, Taro will cease commercial sales and related promotional activities for Keveyis and bear all costs associated with its manufacture. In the near term, patients will continue to receive the medicine through Diplomat as the Company evaluates the best option for keeping pharmacy dispensing fees to patients as low as possible. TARO: 141.22 (-0.92)
American CryoStem Corporation Retains Investor Relations Partners as Investor Relations Counsel
Marketwired - Fri Apr 01, 7:00AM CDT
American CryoStem Corporation (OTC PINK: CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced that it has retained Investor Relations Partners (IRP) to expand the Company's strategic investor relations program.
TARO: 141.22 (-0.92), HOT: 76.59 (-1.21)
Taro posts 3Q profit
Automated Insights - Wed Feb 10, 4:33PM CST
HAIFA BAY, Israel (AP) _ Taro Pharmaceutical Industries Ltd. (TARO) on Wednesday reported fiscal third-quarter profit of $189 million.
TARO: 141.22 (-0.92)
Taro Provides Results for December 31, 2015
BusinessWire - Wed Feb 10, 4:15PM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company"
today provided unaudited financial results for the three and nine months ended December 31, 2015. TARO: 141.22 (-0.92)
CORRECTING and REPLACING Taro to Announce Third Quarter Results on February 10, 2016
BusinessWire - Wed Feb 03, 1:57PM CST
The date at the end of the first paragraph of release dated February 2, 2016 should read: Wednesday, February 10, 2016 (instead of Tuesday, February 10, 2016).
TARO: 141.22 (-0.92)
Taro to Announce Third Quarter Results on February 10, 2016
BusinessWire - Tue Feb 02, 2:56PM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter and nine months ended December 31, 2015, after the close of market on Tuesday, February 10, 2016.
TARO: 141.22 (-0.92)
Taro Provides Results for September 30, 2015
BusinessWire - Tue Nov 03, 5:06PM CST
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company"
today provided unaudited financial results for the three and six months ended September 30, 2015. TARO: 141.22 (-0.92)
Taro to Announce Second Quarter Results on November 3, 2015
BusinessWire - Tue Oct 27, 3:53PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the quarter and six months ended September 30, 2015, on Tuesday, November 3, 2015, after the close of the Market.
TARO: 141.22 (-0.92)
Taro Pharmaceutical Industries introduces Keveyis 50 mg tablets for treating primary hyperkalemic and hypokalemic periodic paralysis
M2 - Tue Sep 22, 3:16AM CDT
Pharmaceutical company Taro Pharmaceutical Industries (NYSE:TARO) disclosed on Monday the launch of Keveyis (dichlorphenamide) 50 mg Tablets for the treatment of primary hyperkalemic and hypokalemic periodic paralysis and related variants in the US market.
TARO: 141.22 (-0.92)
Taro's Keveyis(TM) (dichlorphenamide) 50 mg Tablets Now Available for the Treatment of Primary Hyperkalemic and Hypokalemic Periodic Paralysis
BusinessWire - Mon Sep 21, 12:28PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that Keveyis(TM) (dichlorphenamide) 50 mg Tablets, the first medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of primary hyperkalemic and hypokalemic periodic paralysis and related variants, is now available for appropriate patients through its specialty pharmacy partner, Diplomat. Periodic paralysis is a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis.[1] It is estimated to affect approximately 5,000 people in the United States, up to 70 percent of which are currently undiagnosed.[2]
TARO: 141.22 (-0.92)
Taro Pharmaceutical Industries wins US FDA approval for Keveyis 50 mg tablets for treating primary hyperkalemic and hypokalemic periodic paralysis
M2 - Tue Aug 11, 4:47AM CDT
Pharmaceutical company Taro Pharmaceutical Industries (NYSE:TARO) revealed on Monday the receipt of the US Food and Drug Administration's (FDA) approval for Keveyis (dichlorphenamide) 50 mg Tablets for the treatment of primary hyperkalemic and hypokalemic periodic paralysis.
TARO: 141.22 (-0.92)
FDA Approves Taro's Keveyis(TM) (dichlorphenamide) 50 mg Tablets for Primary Hyperkalemic and Hypokalemic Periodic Paralysis
BusinessWire - Mon Aug 10, 7:30AM CDT
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that the U.S. Food and Drug Administration (FDA) has approved Keveyis(TM) (dichlorphenamide) 50 mg Tablets for the treatment of primary hyperkalemic and hypokalemic periodic paralysis, a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis [1]. Keveyis is the first medicine approved by the FDA for the treatment of primary periodic paralysis, which is estimated to affect approximately 5,000 people in the United States [2].
TARO: 141.22 (-0.92)
Taro Provides Results for Quarter Ended June 2015
BusinessWire - Thu Aug 06, 4:19PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company"
today provided unaudited financial results for the quarter ended June 30, 2015. TARO: 141.22 (-0.92)
Taro to Announce First Quarter Results on August 6, 2015
BusinessWire - Thu Jul 30, 4:09PM CDT
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter and three months ended June 30, 2015, after the close of market on Thursday, August 6, 2015.
TARO: 141.22 (-0.92)
